Ecole Polytechnique Federale de Lausanne

Medical research

A tool to interrogate a new class of drugs

In 2014, the European Medicines Agency approved the drug Tecfidera for the treatment of relapsing multiple sclerosis, a neurodegenerative disease that affects millions of people worldwide. In multiple sclerosis, inflammation ...

Oncology & Cancer

New immunotherapy method targets tumor tissue only

Immunotherapy drugs are promising new weapons in the fight against cancer, but they are so strong that they can be toxic to the rest of the human body. The basic idea behind immunotherapy drugs is simple. Doctors inject special ...

Diseases, Conditions, Syndromes

Improving contact-tracing apps in the COVID-19 era

An international collaboration with EPFL has developed a method to improve the performance of COVID-19 contact-tracing apps by taking into account a user's recent contacts, risk levels and shared information about tests and ...

Oncology & Cancer

Lung cancer: Hope for increasing immunotherapy efficacy

Lung cancer is the leading cause of cancer-related death. Current treatments employ immunotherapy, often in combination with chemotherapy, but benefits to patients remain slight. In a pre-clinical study, EPFL researchers ...

Neuroscience

Brain fingerprints help doctors detect neurological disease

An EPFL scientist has found that brain fingerprints—or maps of the neural connections within our brain—can be used to detect a decline in cognitive ability. That's because the fingerprints are harder to detect in people ...

Neuroscience

Brain 'noise' keeps nerve connections young

Neurons communicate through rapid electrical signals that regulate the release of neurotransmitters, the brain's chemical messengers. Once transmitted across a neuron, electrical signals cause the juncture with another neuron, ...

Diseases, Conditions, Syndromes

New blood test measures immunity against SARS-CoV-2

The Lausanne University Hospital (CHUV) and EPFL teamed up to develop a new test that's sensitive enough to measure the amount of SARS-CoV-2 neutralizing antibodies present in the bloodstream. The scientists' discovery, published ...

page 8 from 37